Prognostic Stratification Value of Baseline Serum Amyloid A in Advanced Gastric Cancer Patients Receiving PD ‐1/ PD ‐ L1 Inhibitors
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72473 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 20.11.2026. Verfasst von Sian Chen und 3 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Serum amyloid A (SAA), an acute‐phase protein reflecting systemic inflammatory status, may provide prognostic information in patients with advanced gastric cancer receiving immunotherapy. This study aimed to evaluate the prognostic stratification value of baseline SAA in patients treated with PD‐1/PD‐L1 inhibitors.
Methods
We retrospectively analyzed 87 patients with advanced gastric cancer who received PD‐1/PD‐L1 inhibitor‐based therapy at Zhejiang Cancer Hospital between June 2019 and July 2023. Baseline SAA, C‐reactive protein (CRP), albumin (ALB), and clinical characteristics were collected at treatment initiation. Optimal cut‐off values were determined using X‐tile analysis. Survival outcomes were evaluated using Kaplan–Meier analysis and Cox proportional hazards regression models.
Results
The optimal cut‐off value for baseline SAA was 13 mg/L. Compared with patients with SAA > 13 mg/L, those with SAA ≤ 13 mg/L had significantly longer overall survival (OS) (15.8 vs. 10.8 months, p = 0.004) and a lower risk of death (HR = 0.51, 95% CI 0.33–0.81). Progression‐free survival (PFS) was also improved in the SAA ≤ 13 mg/L group (HR = 0.53, 95% CI 0.33–0.85; log‐rank p = 0.007). No significant difference was observed in Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1‐based treatment response between groups. Patients with SAA > 13 mg/L showed higher CRP levels and lower ALB levels (both p < 0.001). In multivariate analysis, peritoneal metastasis and prior radical gastrectomy remained independently associated with OS, whereas SAA lost statistical significance after adjustment.
Conclusions
Elevated baseline SAA was associated with poorer OS and PFS in patients with advanced gastric cancer receiving PD‐1/PD‐L1 inhibitors. SAA may reflect systemic inflammatory–host status and serve as an accessible biomarker for prognostic risk stratification, although prospective validation is required.
Zitieren
APA
Chen, S., Fang, Y., Zhao, Y., & Shi, Z. (2026). Prognostic Stratification Value of Baseline Serum Amyloid A in Advanced Gastric Cancer Patients Receiving PD ‐1/ PD ‐ L1 Inhibitors. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72473
Vancouver
Chen S, Fang Y, Zhao Y, Shi Z. Prognostic Stratification Value of Baseline Serum Amyloid A in Advanced Gastric Cancer Patients Receiving PD ‐1/ PD ‐ L1 Inhibitors. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72473
BibTeX
@article{Chen2026,
author = {Chen, Sian and Fang, Yulu and Zhao, Yifan and Shi, Zhong},
title = {Prognostic Stratification Value of Baseline Serum Amyloid A in Advanced Gastric Cancer Patients Receiving PD ‐1/ PD ‐ L1 Inhibitors},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72473}
}
EUVIMED